NEWS
Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease
Gain Therapeutics has presented data at the Federation of European Neuroscience Societies (FENS) Forum 2024 showing that their lead therapeutic candidate, GT-02287, has significantly improved cognitive function and activities of daily living in a preclinical model of GBA1 Parkinson's disease (GBA1-PD). The study demonstrated a reversal of motor function deficits in mice, assessed through nest-building and motor performance tests. The GT-02287 therapy was administered orally and showed promising results in enhancing daily activities reflecting human cognitive performance. The presentation, made on June 27, 2024, aligns with the company’s ongoing Phase 1 clinical study aimed at delivering effective treatments for Parkinson’s disease.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment